Your browser doesn't support javascript.
loading
Recurrence pattern and TP53 mutation in upper urinary tract urothelial carcinoma.
Chen, Chung-Hsin; Dickman, Kathleen G; Huang, Chao-Yuan; Shun, Chia-Tung; Tai, Huai-Ching; Huang, Kuo-How; Wang, Shuo-Meng; Lee, Yuan-Ju; Grollman, Arthur P; Pu, Yeong-Shiau.
Afiliação
  • Chen CH; Department of Urology, National Taiwan University Hospital, Taipei, Taiwan.
  • Dickman KG; Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, USA.
  • Huang CY; Department of Medicine, Stony Brook University, Stony Brook, NY, USA.
  • Shun CT; Department of Urology, National Taiwan University Hospital, Taipei, Taiwan.
  • Tai HC; Department of Forensic Medicine and Pathology, National Taiwan University Hospital, Taipei, Taiwan.
  • Huang KH; Department of Urology, National Taiwan University Hospital, Taipei, Taiwan.
  • Wang SM; Department of Urology, National Taiwan University Hospital, Taipei, Taiwan.
  • Lee YJ; Department of Urology, National Taiwan University Hospital, Taipei, Taiwan.
  • Grollman AP; Department of Urology, National Taiwan University Hospital, Taipei, Taiwan.
  • Pu YS; Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, USA.
Oncotarget ; 7(29): 45225-45236, 2016 Jul 19.
Article em En | MEDLINE | ID: mdl-27286260
ABSTRACT
TP53 mutation patterns are associated with prognosis of various cancers. This study was designed to investigate the association between TP53 mutation patterns and recurrence patterns in upper urinary tract urothelial carcinoma (UTUC) patients. A total of 165 consecutive UTUC patients who underwent nephroureterectomies were enrolled for measuring mutation patterns of TP53 gene from exome 2 to 11. Bladder recurrence, contralateral UTUC recurrence, and metastases were compared among groups by using log-rank test and Cox proportional hazard model. Single base substitution as an AT to TA transversion was noted in 55 (33.3%) patients (AT group). Forty-two (25.5%) patients had TP53 mutations with only other than AT to TA transversion (NAT group), and 68 patients (41.2%) had wide-type TP53 (WT group). AT group was predominately female (64%, 52%, 29%, respectively), had a higher incidence of end-stage renal disease (24%, 14%, 10%, respectively), and had more high-grade tumors (82%, 74%, 62%, respectively) compared to NAT and WT groups. With adjustment of tumor grade/stages, bladder and contralateral UTUC recurrence-free survival duration was shortest in NAT (p < 0.001) and AT group (p < 0.001), respectively. NAT group had a shorter metastasis-free survival duration than the other two groups combined (p = 0.018). As a result, AT to TA transversion increased contralateral UTUC recurrence risk, but other mutations in TP53 raised the hazard of bladder recurrence and metastases. Therefore, TP53 mutation pattern may be a useful biomarker to predict recurrence patterns of UTUC patients.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Genes p53 / Mutação / Recidiva Local de Neoplasia Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Genes p53 / Mutação / Recidiva Local de Neoplasia Idioma: En Ano de publicação: 2016 Tipo de documento: Article